Document Type
Article
Publication Date
2016
College/Unit
School of Medicine
Department/Program/Center
Medicine
Abstract
Colorectal cancer is the second most common cause of cancer deaths for both men and women, and the third most common cause of cancer in the U.S. Toxicity of current chemotherapeutic agents for colorectal cancer, and emergence of drug resistance underscore the need to develop new, potentially less toxic alternatives. Our recent cross-sectional study in a large Appalachian population, showed a strong, inverse, dose–response association of serum perfluorooctane sulfonate (PFOS) levels to prevalent colorectal cancer, suggesting PFOS may have therapeutic potential in the prevention and/or treatment of colorectal cancer. In these preliminary studies using a mouse model of familial colorectal cancer, the APCmin mouse, and exposures comparable to those reported in human populations, we assess the efficacy of PFOS for reducing tumor burden, and evaluate potential dose–response effects.
Digital Commons Citation
Wimsatt, Jeffrey; Villers, Meghan; Thomas, Laurel; Kamarec, Stacey; Montgomery, Caitlin; Yeung, Leo W. Y.; Hu, Yanqing; and Innes, Kim, "Oral Perfluorooctane Sulfonate (PFOS) Lessens Tumor Development In The APCmin Mouse Model of Spontaneous Familial Adenomatous Polyposis" (2016). Faculty & Staff Scholarship. 1483.
https://researchrepository.wvu.edu/faculty_publications/1483
Source Citation
Wimsatt, J., Villers, M., Thomas, L., Kamarec, S., Montgomery, C., Yeung, L. W. Y., Hu, Y., & Innes, K. (2016). Oral perfluorooctane sulfonate (PFOS) lessens tumor development in the APCmin mouse model of spontaneous familial adenomatous polyposis. BMC Cancer, 16(1). https://doi.org/10.1186/s12885-016-2861-5
Comments
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.